The fight for our genes heads to court
By Editorial,
San Francisco Chronicle [cites Marcy Darnovksy]
| 05. 23. 2009
Twenty percent of your body belongs to someone else.
Don't believe us? Check the U.S. Patent Office. Twenty percent of all human genes have been patented, mostly by private companies and research institutions. These patents are crippling the ability of scientists to study diseases and restricting patients from getting the information they need to make important medical decisions about their health.
This month, six breast cancer patients filed suit against Myriad Genetics, a company that owns both the patent on two genes that are associated with an increased risk for breast cancer and ovarian cancer and the patent on testing to measure those risks. Some of these women are suing because they can't afford the $3,000 fee Myriad charges to determine their risk for breast or ovarian cancer. Some of them are suing because, thanks to Myriad's patent, they can't get second opinions about whether they should have their breasts or ovaries removed - no one else is allowed to perform another test for them.
All of them are suing because they did not, and should not, expect to have...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...